Tevogen bio’s chief scientific officer sells shares totaling $250k

Neal Flomenberg, the Chief Scientific Officer and Global R&D Lead at Tevogen Bio Holdings Inc. (NASDAQ:TVGN), recently sold shares amounting to a total of $250,006. The transactions occurred over three consecutive days, from March 4 to March 6, 2025, with prices ranging from $1.10 to $1.28 per share.

On March 4, Flomenberg sold 14,639 shares at a weighted average price of $1.28. The following day, March 5, he disposed of 110,659 shares at an average price of $1.21. The final transaction on March 6 involved the sale of 88,519 shares at an average price of $1.10.

According to the filing, these sales were executed to satisfy tax obligations related to the vesting and settlement of restricted stock units and were not made at Flomenberg’s discretion. Following these transactions, Flomenberg holds 4,040,485 shares in Tevogen Bio.

In other recent news, Tevogen Bio has been in the spotlight with several key developments. The company received a Buy rating from Boral (OTC:BOALY) Capital, which set a price target of $10. This reflects confidence in Tevogen’s innovative approach to T cell immunotherapies, particularly its lead product, TVGN-489, aimed at providing targeted immune protection for high-risk COVID-19 patients. Additionally, Tevogen Bio announced an expanded collaboration with Microsoft (NASDAQ:MSFT) to enhance its PredicTcell technology using AI and cloud capabilities. This partnership is expected to advance the company’s predictive precision T-cell targeting efforts. The collaboration was announced after the market closed last week, highlighting a strategic move to leverage cutting-edge technology in its development processes. These recent developments underscore Tevogen’s ongoing efforts to advance its clinical programs and strengthen its position in the biotechnology field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.